07:00 , Jun 17, 2013 |  BioCentury  |  Strategy

Externalizing Astellas

With a stocked late-stage pipeline, Astellas Pharma Inc. has decided to restructure its R&D and give more attention to finding early stage programs by looking outside. The Japanese pharma will eliminate much of its bricks-and-mortar...
07:00 , Sep 6, 2010 |  BC Week In Review  |  Clinical News

AGS-16M8F: Phase I started

Astellas' Agensys Inc. subsidiary began an open-label, dose-escalation, U.S. Phase I trial to evaluate AGS-16M8F in about 50 patients. AGS-16M8F uses antibody-drug conjugate technology from Seattle Genetics Inc. (NASDAQ:SGEN, Bothell, Wash.), which received...